Predicting treatment response to IL6R blockers in rheumatoid arthritis

Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis

(2019) Elizabeth M A Hensor et al.   RHEUMATOLOGY

Association of serum Tocilizumab trough concentrations with clinical disease activity index scores in adult rheumatoid arthritis patients.

(2019) Uri Arad et al.   JOURNAL OF RHEUMATOLOGY

Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

(2018) Siddharth Singh et al.   PLoS One

Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission

(2018) Shinya Tasaki et al.   Nature Communications

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

(2018) Jonathan Massey et al.   PHARMACOGENOMICS JOURNAL

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

(2017) C.A. Wijbrandts et al.   MAYO CLINIC PROCEEDINGS

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

(2017) Laura C. Cappelli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register

(2017) James M. Gwinnutt et al.   Arthritis & Rheumatology

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort

(2016) Meghna Jani et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study

(2016) Yuan An et al.   CLINICAL RHEUMATOLOGY

Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis

(2016) Mar Maldonado-Montoro et al.   PHARMACOLOGICAL RESEARCH

Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice

(2016) Javier Narváez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis

(2015) Meghna Jani et al.   LANCET

Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study

(2015) Tadashi Okano et al.   RHEUMATOLOGY INTERNATIONAL

Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

(2015) Shintaro Hirata et al.   ARTHRITIS RESEARCH & THERAPY

Pretreatment Prediction of Individual Rheumatoid Arthritis Patients’ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers

(2015) Kazuko Uno et al.   PLoS One

AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha

(2014) A. Rafique et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0007 Prediction of Therapeutic Responses to TOCILIZUMAB in Patients with Rheumatoid Arthritis Using Biomarkers Identified by Genome-Wide DNA Microarray Analysis in Peripheral Blood Mononuclear Cells

(2014) Y. Sanayama et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0453 Response to TOCILIZUMAB in Rheumatoid Arthritis is not Influenced by the Body Mass Index of the Patient

(2014) Y.-M. Pers et al.   ANNALS OF THE RHEUMATIC DISEASES

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis

(2014) Anaïs Gardette et al.   JOINT BONE SPINE

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

(2014) James Bluett et al.   RHEUMATOLOGY

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis

(2014) C. I. Daien et al.   RHEUMATOLOGY

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

(2014) Glynn Dennis et al.   ARTHRITIS RESEARCH & THERAPY

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

(2013) Naoshi Nishina et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetics of rheumatoid arthritis contributes to biology and drug discovery

(2013) Yukinori Okada et al.   NATURE

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

(2013) Yves-Marie Pers et al.   RHEUMATOLOGY

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

(2013) R.J. Maneiro et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis

(2013) Lis Cordingley et al.   ARTHRITIS CARE & RESEARCH

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis

(2013) Jianmei Wang et al.   BMJ Open

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis

(2012) J Wang et al.   PHARMACOGENOMICS JOURNAL

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

(2011) Yusuf Yazici et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

(2010) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES